EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review

Maria T Cruz Carreras, Francisco González Landrón, Natalie López, Leticia Padrón Alcántara, Dana M Markides, Kathryn J Burk, Patrick Chaftari

Supportive Care in Cancer · 2025-10 · 33 (10)

DOI: 10.1007/s00520-025-09952-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Supportive Care in Cancer, online erschienen am 07.10.2025. Verfasst von Maria T Cruz Carreras und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mcruz3@mdanderson.org. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Hematologic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) targeting CTLA-4, PD-1, and PD-L1 have transformed cancer therapy but may trigger rare, sometimes fatal hematologic immune-related adverse events (irAEs). The most frequent hematologic irAEs are anemia, thrombocytopenia, and pancytopenia, which occur more often with CTLA-4 inhibitors and in patients receiving combination therapy. Risk is heightened when ICIs are combined with chemotherapy or radiation. Common symptoms include fatigue, abnormal bleeding, easy bruising, and recurrent infections. Diagnosis relies on laboratory studies, histologic evaluation, and review of medication history. Management typically involves ICI discontinuation and immunosuppression with corticosteroids or rituximab; adjunctive options include IVIG, transfusions, or plasmapheresis depending on severity. Research is also exploring cytokines such as IL-2, IL-7, and IL-15 for ICI-related lymphopenia. Current evidence is drawn mainly from case reports and small series, highlighting the need for larger studies to clarify incidence, mechanisms, and optimal management. Recent pharmacovigilance and outcomes data confirm these events remain rare and can present late, underscoring the need for long-term surveillance and robust monitoring systems [Fletcher K and Johnson DB 2024; Durbin SM et al. 2025; Yang Y. et al. 2024; Han X. et al. 2025].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHematologic DiseasesHumans

Stichwörter der Autor:innen

CTLA-4 Antigen / antagonists & inhibitorsHematologic Diseases / chemically inducedImmune Checkpoint Inhibitors / adverse effectsImmunosuppressive Agents / therapeutic usePharmacovigilanceProgrammed Cell Death 1 Receptor / antagonists & inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mcruz3@mdanderson.org.
  • Department of Medicine, Ponce Health Sciences University, Ponce, PR, USA.
  • Department of Medicine, Universidad Anáhuac, Querétaro, México.
  • Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Zitieren

APA

Cruz Carreras, M. T., González Landrón, F., López, N., Padrón Alcántara, L., Markides, D. M., Burk, K. J., & Chaftari, P. (2025). Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. Supportive Care in Cancer, 33(10). https://doi.org/10.1007/s00520-025-09952-2

Vancouver

Cruz Carreras MT, González Landrón F, López N, Padrón Alcántara L, Markides DM, Burk KJ, et al. Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. Supportive Care in Cancer. 2025;33(10). doi:10.1007/s00520-025-09952-2

BibTeX
@article{CruzCarreras2025,
  author = {Cruz Carreras, Maria T and González Landrón, Francisco and López, Natalie and Padrón Alcántara, Leticia and Markides, Dana M and Burk, Kathryn J and Chaftari, Patrick},
  title = {Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review},
  journal = {Supportive Care in Cancer},
  year = {2025},
  volume = {33},
  number = {10},
  doi = {10.1007/s00520-025-09952-2}
}
Kostenlos starten →